Carvykti

Indications for Use

Carvykti is used to treat adults with multiple myeloma that is relapsed or refractory. This means the cancer has either come back after treatment (relapsed) or did not respond to treatment (refractory).

This medication is specifically for patients who have already received other types of therapy. These typically include:

• A proteasome inhibitor.
• An immunomodulatory agent.
• An anti-CD38 monoclonal antibody.

How It Is Used

Carvykti is a personalized treatment known as CAR T-cell therapy. It is made using the patient's own white blood cells (T cells). These cells are collected from the patient, modified in a laboratory to help them recognize and attack specific proteins on the surface of myeloma cells, and then infused back into the patient's bloodstream.

Because it is a specialized treatment, it is only administered in certified healthcare facilities by medical professionals who are trained to manage the process and monitor for potential reactions.

How Carvykti Works

Carvykti is a type of treatment known as chimeric antigen receptor (CAR) T-cell therapy. It is an autologous treatment, which means it is manufactured using a patient's own white blood cells to create a personalized medicine.

The mechanism involves several key steps to help the body fight cancer:

• Cell Collection: T cells, which are immune system cells that normally fight infections, are collected from the patient's blood through a process called leukapheresis.
• Genetic Engineering: These T cells are sent to a laboratory where they are genetically modified. A new gene is added to the cells so they can produce special receptors on their surface called chimeric antigen receptors (CARs).
• Targeting Cancer: The CARs are specifically designed to identify and bind to a protein called B-cell maturation antigen (BCMA). This protein is found in high amounts on the surface of multiple myeloma cells.
• Activation and Destruction: Once the modified T cells are infused back into the patient's bloodstream, they circulate and search for cells expressing BCMA. When the CAR T cells attach to the myeloma cells, they become activated and begin to kill the cancer cells.

By using the patient's own modified cells to target a specific protein on the cancer, Carvykti helps the immune system focus its attack directly on the disease.

Common Side Effects

Many people experience side effects during or after treatment with Carvykti. Common symptoms include:

• Fever and chills
• Feeling very tired or weak
• Cough and shortness of breath
• Nausea, diarrhea, or constipation
• Muscle or joint pain
• Headache and dizziness
• Fast or irregular heartbeat
• Swelling in the arms or legs

Serious Side Effects

Some side effects can be severe and may require hospitalization. Seek medical help immediately for the following:

• Cytokine Release Syndrome (CRS): This is a serious immune system reaction. Symptoms include high fever, chills, low blood pressure, and trouble breathing.
• Neurological Issues: This treatment can affect the brain and nervous system, causing confusion, tremors, loss of balance, difficulty speaking, or seizures.
• Increased Risk of Infection: Carvykti can weaken the immune system, making it harder to fight off serious infections.
• Low Blood Cell Counts: The medication may cause a significant decrease in blood cells that help fight infection, carry oxygen, or stop bleeding.
• Secondary Cancers: There is a risk of developing new blood cancers after receiving this therapy.

Boxed Warnings

Carvykti has several boxed warnings, which are the most serious warnings from the FDA. These include:

• Cytokine Release Syndrome (CRS): A systemic inflammatory response that can be life-threatening. Symptoms may include high fever, chills, low blood pressure, and difficulty breathing.
• Neurologic Toxicities: This includes Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which can cause confusion, altered consciousness, or seizures. Other delayed neurologic risks include Parkinsonism and Guillain-Barré syndrome.
• Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS): A life-threatening condition involving overactive immune cells.
• Prolonged Cytopenia: Long-lasting low blood cell counts (white blood cells, red blood cells, or platelets) that increase the risk of bleeding and infection.
• Secondary Malignancies: There is a risk of developing new cancers, specifically T-cell malignancies, after treatment with CAR-T cell therapies.

Immune Effector Cell-Associated Enterocolitis

The FDA has identified a risk of immune effector cell-associated enterocolitis. This condition involves inflammation of the intestines and may cause severe abdominal pain or diarrhea.

Infections and Immune System Effects

Treatment can lead to severe or life-threatening infections. It may also cause hypogammaglobulinemia, a condition where the body does not produce enough antibodies, requiring long-term monitoring and potential replacement therapy.

Monitoring and Safety Precautions

Due to the risk of serious side effects, patients are typically required to stay within a certain distance of the treatment facility for at least four weeks following the infusion. Healthcare providers monitor for signs of toxicity daily during the initial period.

Patients are advised not to drive or operate heavy machinery for at least eight weeks after receiving Carvykti because of the risk of sudden confusion, dizziness, or seizures.

Pregnancy

There is no available data on the use of Carvykti in pregnant individuals. Because animal reproductive studies have not been conducted, it is unknown if the medication can cause harm to a fetus or affect the ability to have children. Due to these unknown risks, Carvykti is not recommended for use during pregnancy.

Healthcare providers typically require a negative pregnancy test for individuals of childbearing potential before starting treatment. It is important to discuss effective methods of contraception with a healthcare professional, as birth control is usually recommended during and after the treatment process.

Breastfeeding

It is not known whether Carvykti is present in human breast milk or if it has any effect on a nursing infant or milk production. Because the safety of breastfeeding while receiving this medication has not been established, it is generally not recommended. Patients should consult with their healthcare team to discuss the risks and benefits of breastfeeding versus alternative feeding options during treatment.

Available Forms

Carvykti is supplied as a cell suspension for intravenous infusion. It is a chimeric antigen receptor (CAR) T-cell therapy that is custom-manufactured for each individual patient.

The medication is created using the patient's own white blood cells, which are collected and genetically modified before being returned to the patient. The final product is provided in one or more infusion bags containing the modified cells suspended in a specialized solution.

FDA Approval and Indications

Carvykti (ciltacabtagene autoleucel) is a genetically modified autologous T-cell immunotherapy approved by the FDA for the treatment of adults with relapsed or refractory multiple myeloma. It is indicated for patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.

Boxed Warning and Safety Communications

The FDA has issued a Boxed Warning for Carvykti because it can cause severe or life-threatening reactions. These include:

• Cytokine Release Syndrome (CRS): A serious systemic inflammatory response.
• Neurologic Toxicities: Including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Parkinsonism, and Guillain-Barré syndrome.
• HLH/MAS: Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome.
• Prolonged Cytopenia: Severe and long-lasting low blood cell counts.
• Immune effector cell-associated enterocolitis: A recently identified risk involving severe inflammation of the intestines.

The FDA also requires the labeling to include a warning about the risk of developing secondary T-cell malignancies. Patients treated with Carvykti should be monitored for life for the development of new cancers.

REMS Program

Due to the risk of severe toxicities, Carvykti is only available through a restricted program called the Carvykti Risk Evaluation and Mitigation Strategy (REMS). Under this program, the drug can only be dispensed and administered at certified healthcare facilities that have specialized training and immediate access to medications required to treat severe reactions.

Factors Affecting Cost

The cost of Carvykti can vary significantly based on several factors, including the treatment facility, insurance coverage, and the specific needs of the patient during the recovery period.

List Price and Manufacturing

Carvykti is a personalized CAR-T cell therapy. Because each dose is custom-made for an individual patient using their own immune cells, the manufacturing process is complex and expensive. The list price for the medication is high, but this is often not the amount a patient pays directly.

Additional Medical Costs

The total expense of treatment usually includes more than just the drug itself. Patients should consider the costs of:

• Pre-treatment procedures, such as leukapheresis (collecting white blood cells).
• Hospital stays for the infusion and the required monitoring period afterward.
• Medications used to manage side effects, such as cytokine release syndrome.
• Follow-up appointments and laboratory tests.

Insurance and Assistance

Many insurance providers, including Medicare and private insurers, cover Carvykti for its approved uses. However, patients may still face out-of-pocket costs like deductibles or coinsurance. The manufacturer often provides patient support programs to help with insurance navigation and financial assistance for those who qualify.